GBA2

Across TCGA pan-cancer cohorts, GBA2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GBA2 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher GBA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GBA2 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

OV, SKCM, and LUSC are the cancer types where GBA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	IV	0.076	0.759	.014	12	view →
SKCM	DFS	Median	All	0.061	0.766	<.001	12	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	9	view →
STAD	OS	Median	IV	0.805	0.283	.031	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.935	0.617	.019	4	view →
COAD	OS	Median	All	0.500	0.808	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GBA2–OV (OS)

Open the OV breakdown →